Pfizer Gives Gov't More Time To Study $2.3B Trillium Deal
Pfizer Inc. has voluntarily provided the Federal Trade Commission an extra 30 days to review its planned $2.3 billion takeover of blood cancer drugmaker Trillium Therapeutics Inc. for antitrust issues....To view the full article, register now.
Already a subscriber? Click here to view full article